Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorasidenib PK in Hepatic Impairment
NCT05674474Phase 1Completed
- Sponsor
- Servier
- Start
- Mar 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vorasidenib in glioma (2 arms), sponsored by Servier. Primary endpoints: Maximum Observed Plasma Concentration, Time to Reach Maximum Observed Plasma Concentration and 2 more. Started Mar 2023; status: completed.
02
Drugs
vorasidenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT05674474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05674474.